Surface-engineered liposomal particles of calcium ascorbate with fenugreek galactomannan enhanced the oral bioavailability of ascorbic acid: a randomized, double-blinded, 3-sequence, crossover study.

17 So, the reported enhancement in ascorbate bioavailability from FC+ is highly significant, since a dosage as high as 2000 mg of CAAS × 3 per day has shown to provide only 250 μM plasma concentration. 42 Liposomal formulation of CAAS was achieved with significant encapsulation efficiency of 95.3 ± 0.55%. 29 In vitro release studies showed that the powder form of FC+ allowed the sustained release of CAAS by controlling the diffusion process through the galactomannan network, as described by Nguyen et al. , for surface modified liposomes. 23 The tablets possess relatively more delayed release kinetics as compared to the granular powder form of FC+ used in capsules.

also in 132,142 other papers